ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth

19.5.2026 08:00:00 CEST | Business Wire | Press Release

ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/

Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical development.

As part of this transition, co-founder Bertrand Magy will move into the role of Chief Operating Officer, and co-founder Max Houry will assume the role of Chief Business Officer. Mr. Magy will focus on operations and the continued development of ATB’s proprietary antibody weaponization technology platform, while Mr. Houry will lead business development, strategic partnerships, and licensing activities.

This leadership transition supports ATB’s next stage of growth, with a focus on the validation of ATB’s platform and preparing for clinical development.

Mark Throsby, PhD, Chief Executive Officer of ATB Therapeutics, said: “Since the closing of our EUR 54 million Series A financing in 2024, we have made strong progress in strengthening our team, expanding our capabilities, and validating our science. I am honored to take on the role of CEO and excited to continue working closely with Bertrand, Max, the Board, and the broader ATB team as we advance our mission and bring atbodies closer to patients.”

Bertrand Magy, PhD, co-founder of ATB Therapeutics, said: “From the beginning, ATB has been driven by a shared vision to create a new class of therapies with real patient impact. It has been an extraordinary scientific and entrepreneurial journey, and I am very proud of what we have accomplished so far. I look forward to continuing to work closely with Mark, Max, and the team as we enter this next chapter.”

Max Houry, co-founder of ATB Therapeutics, said: “Over the past years, we have transformed an initial scientific concept into a promising therapeutic platform. Together with Bertrand and Mark, we have built strong foundations for the Company’s future. In my new role, I will focus on translating that momentum into strategic partnerships and business opportunities that can help bring meaningful therapies to patients.”

Mark Throsby earned his PhD in Immunology from Monash University in Melbourne, Australia, and spent four years as a research fellow at CNRS in Paris. He began his industry career at Crucell (acquired by Johnson & Johnson for USD 2.4 billion), where he spent eight years in various roles, including Director of Antibody Discovery. Prior to joining ATB, he served at Merus (acquired by Genmab for USD 8.0 billion) as COO and later CSO, where he played a key role in the development of the bispecific antibody therapeutics petosemtamab and zenocutuzumab. He is an expert in antibody engineering and immunology, with more than a dozen granted patents and > 50 peer-reviewed publications.

About ATB Therapeutics

ATB Therapeutics is an emerging biotechnology company developing atbodies, the next‑generation of weaponized antibody therapies powered by a proprietary portfolio of differentiated payloads with unique modes of action. By integrating these innovative payloads into advanced antibody formats, ATB Therapeutics aims to deliver more precise and potent treatment options for patients across oncology and autoimmune diseases. The company is building a new class of targeted therapeutics designed to overcome limitations of conventional approaches and address significant unmet medical needs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513198633/en/

Contacts

For Media Inquiries, Contact:
ATB Therapeutics
Mark Throsby, CEO
Email: info@atbtherapeutics.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release

A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom